<p>Assenagon Asset Management S.A. 在最近向美国证券交易委员会（SEC）提交的文件中表示，在第三季度将其在 Ocular Therapeutix, Inc.（NASDAQ:OCUL - 免费报告）中的持仓减少了 76.5%。该基金在季度内出售了 148,100 股后，持有该生物制药公司 45,600 股股票。Assenagon Asset Management S.A. 在 Ocular Therapeutix 的持股在最近的报告期末价值为 533,000 美元。</p>
<p>其他一些对冲基金也对该公司的持仓进行了调整。Adage Capital Partners GP L.L.C. 在第一季度将其在 Ocular Therapeutix 的持仓增加了 44.4%。Adage Capital Partners GP L.L.C. 目前持有 5,200,000 股该生物制药公司的股票，价值 38,116,000 美元，此前在上个季度又购买了 1,600,000 股。Deltec Asset Management LLC 在第二季度将其在 Ocular Therapeutix 的股份增加了 2.9%。Deltec Asset Management LLC 目前持有 2,794,892 股该生物制药公司的股票，价值 25,937,000 美元，此前在上个季度又收购了 78,519 股。Invesco Ltd. 在第二季度将其在 Ocular Therapeutix 的股份增加了 91.2%。Invesco Ltd. 目前持有 1,538,846 股该生物制药公司的股票，价值 14,280,000 美元，此前在上个季度又收购了 734,017 股。Paradigm Biocapital Advisors LP 在第一季度获得了 Ocular Therapeutix 的新持仓，价值约 9,632,000 美元。最后，Raymond James Financial Inc. 在第二季度将其在 Ocular Therapeutix 的持仓增加了 142.8%。Raymond James Financial Inc. 目前持有 884,381 股该生物制药公司的股票，价值 8,207,000 美元，此前在上个季度又收购了 520,138 股。机构投资者和对冲基金持有该公司 59.21% 的股票。</p>
<p>获取 <strong>Ocular Therapeutix</strong> 的提醒：</p>
<h2>Ocular Therapeutix 的内部活动</h2>
<p>在 Ocular Therapeutix 的其他新闻中，内部人士 Peter Kaiser 于 10 月 2 日星期四出售了 9,653 股该股票。该股票以平均价格 11.03 美元出售，总价值为 106,472.59 美元。交易后，内部人士持有 194,440 股该公司的股票，价值约 2,144,673.20 美元。这代表其持股减少了 4.73%。该交易已在向 SEC 提交的文件中披露，相关信息可通过 SEC 网站访问。此外，内部人士 Jeffrey S. Heier 于 10 月 2 日星期四出售了 10,502 股该公司的股票。该股票以平均价格 11.04 美元出售，总价值为 115,942.08 美元。交易后，内部人士在公司中持有 249,409 股，价值约 2,753,475.36 美元。此交易代表其持股减少了 4.04%。该销售的披露信息可在 SEC 文件中找到。在上个季度，内部人士出售了价值 359,784 美元的 31,287 股公司股票。2.30% 的股票由内部人士持有。</p>
<h2>Ocular Therapeutix 的价格表现</h2>
<p>OCUL 股票在星期五开盘价为 12.71 美元。该公司的 50 日移动平均价格为 12.28 美元，200 日移动平均价格为 11.67 美元。该公司的债务与股本比率为 0.27，速动比率为 7.78，流动比率为 7.85。Ocular Therapeutix, Inc. 的 52 周低点为 5.78 美元，52 周高点为 16.44 美元。该股票的市值为 27.1 亿美元，市盈率为 -8.83，贝塔值为 0.96。</p>
<p>Ocular Therapeutix（NASDAQ:OCUL - 获取免费报告）最后一次发布财报是在 11 月 4 日星期二。这家生物制药公司报告本季度每股收益为（$0.37），超出市场共识预期的（$0.39）0.02 美元。该公司在本季度的收入为 1454 万美元，而分析师的预期为 1457 万美元。Ocular Therapeutix 的净利润率为 -447.57%，股本回报率为 -86.33%。作为一个整体，分析师预测 Ocular Therapeutix, Inc. 本年度将发布 -0.98 的每股收益。</p>
<h2>分析师设定新的价格目标</h2>
<p>OCUL 已成为几份研究分析师报告的主题。Zacks Research 在 10 月 2 日星期四的研究报告中将 Ocular Therapeutix 的评级从 &#34;强烈卖出&#34; 上调至 &#34;持有&#34;。华尔街 Zen 在 12 月 6 日星期六的研究报告中将 Ocular Therapeutix 的评级从 &#34;持有&#34; 下调至 &#34;卖出&#34;。Needham &amp; Company LLC 在 12 月 8 日星期一重申了 &#34;买入&#34; 的评级，并对 Ocular Therapeutix 的股票设定了 20.00 美元的价格目标。HC Wainwright 在 12 月 8 日星期一将 Ocular Therapeutix 的股票价格目标从 19.00 美元提高至 21.00 美元，并给予该股票 &#34;买入&#34; 的评级。最后，Weiss Ratings 在 10 月 8 日星期三的研究报告中重申了 Ocular Therapeutix 的 &#34;卖出（d-）&#34; 评级。十二位股票研究分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，Ocular Therapeutix 目前的平均评级为 &#34;适度买入&#34;，共识目标价格为 22.56 美元。</p>
<p><strong>查看我们关于 Ocular Therapeutix 的最新研究报告</strong></p>
<h2>Ocular Therapeutix 公司简介</h2>
<p>（免费报告）</p>
<p>Ocular Therapeutix, Inc. 是一家致力于开发创新疗法以治疗眼部疾病和状况的生物制药公司。公司成立于 2011 年，总部位于马萨诸塞州贝德福德，专注于持续释放药物输送平台，旨在解决眼科领域的关键未满足需求。其专有的水凝胶基插入物和密封剂旨在通过直接向眼部组织提供活性药物成分的控制释放来改善患者的依从性和治疗效果。</p>
<p>该公司的旗舰产品 DEXTENZA® 是一种无防腐剂的、持续释放的地塞米松内管插入物，已获得美国批准。</p>
<h2>精选故事</h2>
<ul>
<li>我们更看好的五只股票，而不是 Ocular Therapeutix</li>
<li>在 1 月 1 日之前投资 1,000 美元于这只股票 [不是 NVDA]</li>
<li>将你的 “死钱” 转变为每月 306 美元以上（从这个月开始）</li>
<li>华盛顿准备迎战</li>
<li>奇特的晶体金属性能超过硅达 100 倍</li>
<li>来自奇怪新 “AI 燃料” 的 33,000% 繁荣？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T0NVTA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T0NVTA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元于 Ocular Therapeutix 吗？</h2>
<p>在考虑 Ocular Therapeutix 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前... 而 Ocular Therapeutix 并不在名单上。</p>
<p>虽然 Ocular Therapeutix 目前在分析师中有中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

OCUL

<p>Assenagon Asset Management S.A. 在第三季度将其在 Ocular Therapeutix, Inc. 的持股减少了 76.5%，出售了 148,100 股。该基金目前持有 45,600 股，价值 533,000 美元。其他对冲基金也调整了在该公司的持仓。内部人士在上个季度出售了 31,287 股，价值 359,784 美元。Ocular Therapeutix 的股票在周五开盘价为 12.71 美元。该公司报告第三季度每股亏损 0.37 美元，超出预期 0.02 美元。分析师对该股票的评级意见不一</p>

<p>Assenagon Asset Management S.A. decreased its position in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 76.5% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 45,600 shares of the biopharmaceutical company's stock after selling 148,100 shares during the quarter. Assenagon Asset Management S.A.'s holdings in Ocular Therapeutix were worth $533,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>Assenagon Asset Management S.A. 在最近向美国证券交易委员会（SEC）提交的文件中表示，在第三季度将其在 Ocular Therapeutix, Inc.（NASDAQ:OCUL - 免费报告）中的持仓减少了 76.5%。该基金在季度内出售了 148,100 股后，持有该生物制药公司 45,600 股股票。Assenagon Asset Management S.A. 在 Ocular Therapeutix 的持股在最近的报告期末价值为 533,000 美元。</p>
</div><p>A number of other hedge funds have also made changes to their positions in the company. Adage Capital Partners GP L.L.C. boosted its position in Ocular Therapeutix by 44.4% in the first quarter. Adage Capital Partners GP L.L.C. now owns 5,200,000 shares of the biopharmaceutical company's stock valued at $38,116,000 after buying an additional 1,600,000 shares in the last quarter. Deltec Asset Management LLC raised its stake in shares of Ocular Therapeutix by 2.9% in the second quarter. Deltec Asset Management LLC now owns 2,794,892 shares of the biopharmaceutical company's stock valued at $25,937,000 after acquiring an additional 78,519 shares during the last quarter. Invesco Ltd. raised its stake in shares of Ocular Therapeutix by 91.2% in the second quarter. Invesco Ltd. now owns 1,538,846 shares of the biopharmaceutical company's stock valued at $14,280,000 after acquiring an additional 734,017 shares during the last quarter. Paradigm Biocapital Advisors LP acquired a new position in shares of Ocular Therapeutix in the 1st quarter worth approximately $9,632,000. Finally, Raymond James Financial Inc. grew its position in Ocular Therapeutix by 142.8% during the 2nd quarter. Raymond James Financial Inc. now owns 884,381 shares of the biopharmaceutical company's stock worth $8,207,000 after acquiring an additional 520,138 shares during the last quarter. Institutional investors and hedge funds own 59.21% of the company's stock.</p>
<div class="lb-trans"><p>其他一些对冲基金也对该公司的持仓进行了调整。Adage Capital Partners GP L.L.C. 在第一季度将其在 Ocular Therapeutix 的持仓增加了 44.4%。Adage Capital Partners GP L.L.C. 目前持有 5,200,000 股该生物制药公司的股票，价值 38,116,000 美元，此前在上个季度又购买了 1,600,000 股。Deltec Asset Management LLC 在第二季度将其在 Ocular Therapeutix 的股份增加了 2.9%。Deltec Asset Management LLC 目前持有 2,794,892 股该生物制药公司的股票，价值 25,937,000 美元，此前在上个季度又收购了 78,519 股。Invesco Ltd. 在第二季度将其在 Ocular Therapeutix 的股份增加了 91.2%。Invesco Ltd. 目前持有 1,538,846 股该生物制药公司的股票，价值 14,280,000 美元，此前在上个季度又收购了 734,017 股。Paradigm Biocapital Advisors LP 在第一季度获得了 Ocular Therapeutix 的新持仓，价值约 9,632,000 美元。最后，Raymond James Financial Inc. 在第二季度将其在 Ocular Therapeutix 的持仓增加了 142.8%。Raymond James Financial Inc. 目前持有 884,381 股该生物制药公司的股票，价值 8,207,000 美元，此前在上个季度又收购了 520,138 股。机构投资者和对冲基金持有该公司 59.21% 的股票。</p>
</div><p>Get <strong>Ocular Therapeutix</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Ocular Therapeutix</strong> 的提醒：</p>
</div><h2>Insider Activity at Ocular Therapeutix</h2>
<div class="lb-trans"><h2>Ocular Therapeutix 的内部活动</h2>
</div><p>In other Ocular Therapeutix news, insider Peter Kaiser sold 9,653 shares of the stock in a transaction dated Thursday, October 2nd. The stock was sold at an average price of $11.03, for a total value of $106,472.59. Following the transaction, the insider owned 194,440 shares of the company's stock, valued at approximately $2,144,673.20. This represents a 4.73% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Jeffrey S. Heier sold 10,502 shares of the firm's stock in a transaction dated Thursday, October 2nd. The stock was sold at an average price of $11.04, for a total value of $115,942.08. Following the transaction, the insider owned 249,409 shares in the company, valued at approximately $2,753,475.36. This trade represents a 4.04% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 31,287 shares of company stock worth $359,784. 2.30% of the stock is owned by insiders.</p>
<div class="lb-trans"><p>在 Ocular Therapeutix 的其他新闻中，内部人士 Peter Kaiser 于 10 月 2 日星期四出售了 9,653 股该股票。该股票以平均价格 11.03 美元出售，总价值为 106,472.59 美元。交易后，内部人士持有 194,440 股该公司的股票，价值约 2,144,673.20 美元。这代表其持股减少了 4.73%。该交易已在向 SEC 提交的文件中披露，相关信息可通过 SEC 网站访问。此外，内部人士 Jeffrey S. Heier 于 10 月 2 日星期四出售了 10,502 股该公司的股票。该股票以平均价格 11.04 美元出售，总价值为 115,942.08 美元。交易后，内部人士在公司中持有 249,409 股，价值约 2,753,475.36 美元。此交易代表其持股减少了 4.04%。该销售的披露信息可在 SEC 文件中找到。在上个季度，内部人士出售了价值 359,784 美元的 31,287 股公司股票。2.30% 的股票由内部人士持有。</p>
</div><h2>Ocular Therapeutix Price Performance</h2>
<div class="lb-trans"><h2>Ocular Therapeutix 的价格表现</h2>
</div><p>Shares of OCUL stock opened at $12.71 on Friday. The firm's 50 day moving average price is $12.28 and its two-hundred day moving average price is $11.67. The company has a debt-to-equity ratio of 0.27, a quick ratio of 7.78 and a current ratio of 7.85. Ocular Therapeutix, Inc. has a 52-week low of $5.78 and a 52-week high of $16.44. The stock has a market cap of $2.71 billion, a PE ratio of -8.83 and a beta of 0.96.</p>
<div class="lb-trans"><p>OCUL 股票在星期五开盘价为 12.71 美元。该公司的 50 日移动平均价格为 12.28 美元，200 日移动平均价格为 11.67 美元。该公司的债务与股本比率为 0.27，速动比率为 7.78，流动比率为 7.85。Ocular Therapeutix, Inc. 的 52 周低点为 5.78 美元，52 周高点为 16.44 美元。该股票的市值为 27.1 亿美元，市盈率为 -8.83，贝塔值为 0.96。</p>
</div><p>Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last issued its earnings results on Tuesday, November 4th. The biopharmaceutical company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.02. The company had revenue of $14.54 million during the quarter, compared to analysts' expectations of $14.57 million. Ocular Therapeutix had a negative net margin of 447.57% and a negative return on equity of 86.33%. As a group, analysts forecast that Ocular Therapeutix, Inc. will post -0.98 EPS for the current year.</p>
<div class="lb-trans"><p>Ocular Therapeutix（NASDAQ:OCUL - 获取免费报告）最后一次发布财报是在 11 月 4 日星期二。这家生物制药公司报告本季度每股收益为（$0.37），超出市场共识预期的（$0.39）0.02 美元。该公司在本季度的收入为 1454 万美元，而分析师的预期为 1457 万美元。Ocular Therapeutix 的净利润率为 -447.57%，股本回报率为 -86.33%。作为一个整体，分析师预测 Ocular Therapeutix, Inc. 本年度将发布 -0.98 的每股收益。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新的价格目标</h2>
</div><p>OCUL has been the subject of several research analyst reports. Zacks Research upgraded Ocular Therapeutix from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a research report on Thursday, October 2nd. Wall Street Zen lowered Ocular Therapeutix from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research note on Saturday, December 6th. Needham &amp; Company LLC reaffirmed a &#34;buy&#34; rating and issued a $20.00 price target on shares of Ocular Therapeutix in a report on Monday, December 8th. HC Wainwright increased their price objective on shares of Ocular Therapeutix from $19.00 to $21.00 and gave the stock a &#34;buy&#34; rating in a report on Monday, December 8th. Finally, Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Ocular Therapeutix in a research note on Wednesday, October 8th. Twelve equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, Ocular Therapeutix presently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $22.56.</p>
<div class="lb-trans"><p>OCUL 已成为几份研究分析师报告的主题。Zacks Research 在 10 月 2 日星期四的研究报告中将 Ocular Therapeutix 的评级从 &#34;强烈卖出&#34; 上调至 &#34;持有&#34;。华尔街 Zen 在 12 月 6 日星期六的研究报告中将 Ocular Therapeutix 的评级从 &#34;持有&#34; 下调至 &#34;卖出&#34;。Needham &amp; Company LLC 在 12 月 8 日星期一重申了 &#34;买入&#34; 的评级，并对 Ocular Therapeutix 的股票设定了 20.00 美元的价格目标。HC Wainwright 在 12 月 8 日星期一将 Ocular Therapeutix 的股票价格目标从 19.00 美元提高至 21.00 美元，并给予该股票 &#34;买入&#34; 的评级。最后，Weiss Ratings 在 10 月 8 日星期三的研究报告中重申了 Ocular Therapeutix 的 &#34;卖出（d-）&#34; 评级。十二位股票研究分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，Ocular Therapeutix 目前的平均评级为 &#34;适度买入&#34;，共识目标价格为 22.56 美元。</p>
</div><p><strong>Check Out Our Latest Research Report on Ocular Therapeutix</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Ocular Therapeutix 的最新研究报告</strong></p>
</div><h2>Ocular Therapeutix Profile</h2>
<div class="lb-trans"><h2>Ocular Therapeutix 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.</p>
<div class="lb-trans"><p>Ocular Therapeutix, Inc. 是一家致力于开发创新疗法以治疗眼部疾病和状况的生物制药公司。公司成立于 2011 年，总部位于马萨诸塞州贝德福德，专注于持续释放药物输送平台，旨在解决眼科领域的关键未满足需求。其专有的水凝胶基插入物和密封剂旨在通过直接向眼部组织提供活性药物成分的控制释放来改善患者的依从性和治疗效果。</p>
</div><p>The company's flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.</p>
<div class="lb-trans"><p>该公司的旗舰产品 DEXTENZA® 是一种无防腐剂的、持续释放的地塞米松内管插入物，已获得美国批准。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Ocular Therapeutix</li>
<li>Put $1,000 into this stock by Jan 1 [Not NVDA]</li>
<li>Turn your &#34;dead money&#34; into $306+ monthly (starting this month)</li>
<li>Washington prepares for war</li>
<li>Strange Crystal Metal Outperforms Silicon Up to 100X</li>
<li>33,000% boom from weird new “AI Fuel?”</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Ocular Therapeutix</li>
<li>在 1 月 1 日之前投资 1,000 美元于这只股票 [不是 NVDA]</li>
<li>将你的 “死钱” 转变为每月 306 美元以上（从这个月开始）</li>
<li>华盛顿准备迎战</li>
<li>奇特的晶体金属性能超过硅达 100 倍</li>
<li>来自奇怪新 “AI 燃料” 的 33,000% 繁荣？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T0NVTA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=OCUL"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Ocular Therapeutix Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元于 Ocular Therapeutix 吗？</h2>
</div><p>Before you consider Ocular Therapeutix, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Ocular Therapeutix 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ocular Therapeutix wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前... 而 Ocular Therapeutix 并不在名单上。</p>
</div><p>While Ocular Therapeutix currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Ocular Therapeutix 目前在分析师中有中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Assenagon Asset Management S.A. 出售了 148,100 股 Ocular Therapeutix, Inc.（股票代码：$OCUL）的股票